Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?

Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid the serious containment efforts against COVID-19 that include physical measures, pharmacological repurposing, immunization, and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2022-10, Vol.154, p.113522-113522, Article 113522
Hauptverfasser: Dhawan, Manish, Saied, AbdulRahman A., Mitra, Saikat, Alhumaydhi, Fahad A., Emran, Talha Bin, Wilairatana, Polrat
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113522
container_issue
container_start_page 113522
container_title Biomedicine & pharmacotherapy
container_volume 154
creator Dhawan, Manish
Saied, AbdulRahman A.
Mitra, Saikat
Alhumaydhi, Fahad A.
Emran, Talha Bin
Wilairatana, Polrat
description Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid the serious containment efforts against COVID-19 that include physical measures, pharmacological repurposing, immunization, and genomic/community surveillance. Omicron variant (B.1.1.529) has been identified as a highly modified, contagious, and crucial variant among the five VOCs of SARS-CoV-2. The increased affinity of the spike protein (S-protein), and host receptor, angiotensin converting enzyme-2 (ACE-2), due to a higher number of mutations in the receptor-binding domain (RBD) of the S-protein has been proposed as the primary reason for the decreased efficacy of majorly available vaccines against the Omicron variant and the increased transmissible nature of the Omicron variant. Because of its significant competitive advantage, the Omicron variant and its sublineages swiftly surpassed other variants to become the dominant circulating lineages in a number of nations. The Omicron variant has been identified as a prevalent strain in the United Kingdom and South Africa. Furthermore, the emergence of recombinant variants through the conjunction of the Omicron variant with other variants or by the mixing of the Omicron variant's sublineages/subvariants poses a major threat to humanity. This raises various issues and hazards regarding the Omicron variant and its sublineages, such as an Omicron variant breakout in susceptible populations among fully vaccinated persons. As a result, understanding the features and genetic implications of this variant is crucial. Hence, we explained in depth the evolution and features of the Omicron variant and analyzed the repercussions of spike mutations on infectiousness, dissemination ability, viral entry mechanism, and immune evasion. We also presented a viewpoint on feasible strategies for precluding and counteracting any future catastrophic emergence and spread of the omicron variant and its sublineages that could result in a detrimental wave of COVID-19 cases. [Display omitted] •The emergence of the Omicron variant and its sublineages pose a severe threat.•Significant number of mutations in the Omicron variant has been associated.•The Omicron variant might have evolved separately from all the previous variants.•Omicron and other variants may generate resistant variants to present vaccines.•Genomic surveillance and Omicron-specific vaccines are containm
doi_str_mv 10.1016/j.biopha.2022.113522
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9376347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332222009118</els_id><sourcerecordid>2707876232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-a85085a62852eb2cc7975bef10015425d9ccdbb97ef958d206360273e3e8271b3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhH3DwsRySju04TjiAygoKUqVKlI-j5TiTXS-JvbWzW_XYf06iXYF6qeYw0szomZn3JeQtg5wBK883eePCdm1yDpznjAnJ-TOyYLWErARQz8kClBSZEJyfkFcpbQBAlqJ6SU5ECQJkJRfk4XpwNgZP9yY640d69ilnU0hev6PGt9SNiaZd0zuPZoXpPf29NiNtA71D-seHO5oC7UykZnAtHddIccC4Qm-Rho5GtGFonJ_Jxw1prt9cfL_JluFXxj--Ji860yd8c8yn5OeXzz-WX7Or68tvy4urzBYFjJmpJFTSlLySHBturaqVbLBjAEwWXLa1tW3T1Aq7WlYth3J6kiuBAiuuWCNOyYcDd7trBmwt-jGaXm-jG0y818E4_bjj3Vqvwl7XQpWiUBPg7AiI4XaHadSDSxb73ngMu6S5AlWpkgs-jRaH0UnalCJ2_9Yw0LN7eqMP7unZPX1w7_-JOOmwdxh1sm6WsnWTkKNug3sa8BcPEaHG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2707876232</pqid></control><display><type>article</type><title>Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?</title><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dhawan, Manish ; Saied, AbdulRahman A. ; Mitra, Saikat ; Alhumaydhi, Fahad A. ; Emran, Talha Bin ; Wilairatana, Polrat</creator><creatorcontrib>Dhawan, Manish ; Saied, AbdulRahman A. ; Mitra, Saikat ; Alhumaydhi, Fahad A. ; Emran, Talha Bin ; Wilairatana, Polrat</creatorcontrib><description>Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid the serious containment efforts against COVID-19 that include physical measures, pharmacological repurposing, immunization, and genomic/community surveillance. Omicron variant (B.1.1.529) has been identified as a highly modified, contagious, and crucial variant among the five VOCs of SARS-CoV-2. The increased affinity of the spike protein (S-protein), and host receptor, angiotensin converting enzyme-2 (ACE-2), due to a higher number of mutations in the receptor-binding domain (RBD) of the S-protein has been proposed as the primary reason for the decreased efficacy of majorly available vaccines against the Omicron variant and the increased transmissible nature of the Omicron variant. Because of its significant competitive advantage, the Omicron variant and its sublineages swiftly surpassed other variants to become the dominant circulating lineages in a number of nations. The Omicron variant has been identified as a prevalent strain in the United Kingdom and South Africa. Furthermore, the emergence of recombinant variants through the conjunction of the Omicron variant with other variants or by the mixing of the Omicron variant's sublineages/subvariants poses a major threat to humanity. This raises various issues and hazards regarding the Omicron variant and its sublineages, such as an Omicron variant breakout in susceptible populations among fully vaccinated persons. As a result, understanding the features and genetic implications of this variant is crucial. Hence, we explained in depth the evolution and features of the Omicron variant and analyzed the repercussions of spike mutations on infectiousness, dissemination ability, viral entry mechanism, and immune evasion. We also presented a viewpoint on feasible strategies for precluding and counteracting any future catastrophic emergence and spread of the omicron variant and its sublineages that could result in a detrimental wave of COVID-19 cases. [Display omitted] •The emergence of the Omicron variant and its sublineages pose a severe threat.•Significant number of mutations in the Omicron variant has been associated.•The Omicron variant might have evolved separately from all the previous variants.•Omicron and other variants may generate resistant variants to present vaccines.•Genomic surveillance and Omicron-specific vaccines are containment measures.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2022.113522</identifier><identifier>PMID: 36030585</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>COVID-19 ; Omicron ; Pandemic ; Review ; Sublineages ; Vaccine effectiveness ; Variants</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2022-10, Vol.154, p.113522-113522, Article 113522</ispartof><rights>2022 The Authors</rights><rights>2022 The Authors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-a85085a62852eb2cc7975bef10015425d9ccdbb97ef958d206360273e3e8271b3</citedby><cites>FETCH-LOGICAL-c440t-a85085a62852eb2cc7975bef10015425d9ccdbb97ef958d206360273e3e8271b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0753332222009118$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids></links><search><creatorcontrib>Dhawan, Manish</creatorcontrib><creatorcontrib>Saied, AbdulRahman A.</creatorcontrib><creatorcontrib>Mitra, Saikat</creatorcontrib><creatorcontrib>Alhumaydhi, Fahad A.</creatorcontrib><creatorcontrib>Emran, Talha Bin</creatorcontrib><creatorcontrib>Wilairatana, Polrat</creatorcontrib><title>Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?</title><title>Biomedicine &amp; pharmacotherapy</title><description>Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid the serious containment efforts against COVID-19 that include physical measures, pharmacological repurposing, immunization, and genomic/community surveillance. Omicron variant (B.1.1.529) has been identified as a highly modified, contagious, and crucial variant among the five VOCs of SARS-CoV-2. The increased affinity of the spike protein (S-protein), and host receptor, angiotensin converting enzyme-2 (ACE-2), due to a higher number of mutations in the receptor-binding domain (RBD) of the S-protein has been proposed as the primary reason for the decreased efficacy of majorly available vaccines against the Omicron variant and the increased transmissible nature of the Omicron variant. Because of its significant competitive advantage, the Omicron variant and its sublineages swiftly surpassed other variants to become the dominant circulating lineages in a number of nations. The Omicron variant has been identified as a prevalent strain in the United Kingdom and South Africa. Furthermore, the emergence of recombinant variants through the conjunction of the Omicron variant with other variants or by the mixing of the Omicron variant's sublineages/subvariants poses a major threat to humanity. This raises various issues and hazards regarding the Omicron variant and its sublineages, such as an Omicron variant breakout in susceptible populations among fully vaccinated persons. As a result, understanding the features and genetic implications of this variant is crucial. Hence, we explained in depth the evolution and features of the Omicron variant and analyzed the repercussions of spike mutations on infectiousness, dissemination ability, viral entry mechanism, and immune evasion. We also presented a viewpoint on feasible strategies for precluding and counteracting any future catastrophic emergence and spread of the omicron variant and its sublineages that could result in a detrimental wave of COVID-19 cases. [Display omitted] •The emergence of the Omicron variant and its sublineages pose a severe threat.•Significant number of mutations in the Omicron variant has been associated.•The Omicron variant might have evolved separately from all the previous variants.•Omicron and other variants may generate resistant variants to present vaccines.•Genomic surveillance and Omicron-specific vaccines are containment measures.</description><subject>COVID-19</subject><subject>Omicron</subject><subject>Pandemic</subject><subject>Review</subject><subject>Sublineages</subject><subject>Vaccine effectiveness</subject><subject>Variants</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhi0EokvhH3DwsRySju04TjiAygoKUqVKlI-j5TiTXS-JvbWzW_XYf06iXYF6qeYw0szomZn3JeQtg5wBK883eePCdm1yDpznjAnJ-TOyYLWErARQz8kClBSZEJyfkFcpbQBAlqJ6SU5ECQJkJRfk4XpwNgZP9yY640d69ilnU0hev6PGt9SNiaZd0zuPZoXpPf29NiNtA71D-seHO5oC7UykZnAtHddIccC4Qm-Rho5GtGFonJ_Jxw1prt9cfL_JluFXxj--Ji860yd8c8yn5OeXzz-WX7Or68tvy4urzBYFjJmpJFTSlLySHBturaqVbLBjAEwWXLa1tW3T1Aq7WlYth3J6kiuBAiuuWCNOyYcDd7trBmwt-jGaXm-jG0y818E4_bjj3Vqvwl7XQpWiUBPg7AiI4XaHadSDSxb73ngMu6S5AlWpkgs-jRaH0UnalCJ2_9Yw0LN7eqMP7unZPX1w7_-JOOmwdxh1sm6WsnWTkKNug3sa8BcPEaHG</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Dhawan, Manish</creator><creator>Saied, AbdulRahman A.</creator><creator>Mitra, Saikat</creator><creator>Alhumaydhi, Fahad A.</creator><creator>Emran, Talha Bin</creator><creator>Wilairatana, Polrat</creator><general>Elsevier Masson SAS</general><general>The Author(s). Published by Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?</title><author>Dhawan, Manish ; Saied, AbdulRahman A. ; Mitra, Saikat ; Alhumaydhi, Fahad A. ; Emran, Talha Bin ; Wilairatana, Polrat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-a85085a62852eb2cc7975bef10015425d9ccdbb97ef958d206360273e3e8271b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19</topic><topic>Omicron</topic><topic>Pandemic</topic><topic>Review</topic><topic>Sublineages</topic><topic>Vaccine effectiveness</topic><topic>Variants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhawan, Manish</creatorcontrib><creatorcontrib>Saied, AbdulRahman A.</creatorcontrib><creatorcontrib>Mitra, Saikat</creatorcontrib><creatorcontrib>Alhumaydhi, Fahad A.</creatorcontrib><creatorcontrib>Emran, Talha Bin</creatorcontrib><creatorcontrib>Wilairatana, Polrat</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhawan, Manish</au><au>Saied, AbdulRahman A.</au><au>Mitra, Saikat</au><au>Alhumaydhi, Fahad A.</au><au>Emran, Talha Bin</au><au>Wilairatana, Polrat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>154</volume><spage>113522</spage><epage>113522</epage><pages>113522-113522</pages><artnum>113522</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid the serious containment efforts against COVID-19 that include physical measures, pharmacological repurposing, immunization, and genomic/community surveillance. Omicron variant (B.1.1.529) has been identified as a highly modified, contagious, and crucial variant among the five VOCs of SARS-CoV-2. The increased affinity of the spike protein (S-protein), and host receptor, angiotensin converting enzyme-2 (ACE-2), due to a higher number of mutations in the receptor-binding domain (RBD) of the S-protein has been proposed as the primary reason for the decreased efficacy of majorly available vaccines against the Omicron variant and the increased transmissible nature of the Omicron variant. Because of its significant competitive advantage, the Omicron variant and its sublineages swiftly surpassed other variants to become the dominant circulating lineages in a number of nations. The Omicron variant has been identified as a prevalent strain in the United Kingdom and South Africa. Furthermore, the emergence of recombinant variants through the conjunction of the Omicron variant with other variants or by the mixing of the Omicron variant's sublineages/subvariants poses a major threat to humanity. This raises various issues and hazards regarding the Omicron variant and its sublineages, such as an Omicron variant breakout in susceptible populations among fully vaccinated persons. As a result, understanding the features and genetic implications of this variant is crucial. Hence, we explained in depth the evolution and features of the Omicron variant and analyzed the repercussions of spike mutations on infectiousness, dissemination ability, viral entry mechanism, and immune evasion. We also presented a viewpoint on feasible strategies for precluding and counteracting any future catastrophic emergence and spread of the omicron variant and its sublineages that could result in a detrimental wave of COVID-19 cases. [Display omitted] •The emergence of the Omicron variant and its sublineages pose a severe threat.•Significant number of mutations in the Omicron variant has been associated.•The Omicron variant might have evolved separately from all the previous variants.•Omicron and other variants may generate resistant variants to present vaccines.•Genomic surveillance and Omicron-specific vaccines are containment measures.</abstract><pub>Elsevier Masson SAS</pub><pmid>36030585</pmid><doi>10.1016/j.biopha.2022.113522</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2022-10, Vol.154, p.113522-113522, Article 113522
issn 0753-3322
1950-6007
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9376347
source Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects COVID-19
Omicron
Pandemic
Review
Sublineages
Vaccine effectiveness
Variants
title Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T12%3A01%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omicron%20variant%20(B.1.1.529)%20and%20its%20sublineages:%20What%20do%20we%20know%20so%20far%20amid%20the%20emergence%20of%20recombinant%20variants%20of%20SARS-CoV-2?&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Dhawan,%20Manish&rft.date=2022-10-01&rft.volume=154&rft.spage=113522&rft.epage=113522&rft.pages=113522-113522&rft.artnum=113522&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2022.113522&rft_dat=%3Cproquest_pubme%3E2707876232%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2707876232&rft_id=info:pmid/36030585&rft_els_id=S0753332222009118&rfr_iscdi=true